Zai Lab Limited (NASDAQ:ZLAB) Stock Holdings Lifted by Point72 Asset Management L.P.

Point72 Asset Management L.P. boosted its stake in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 2,006.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 283,600 shares of the company's stock after buying an additional 270,136 shares during the period. Point72 Asset Management L.P. owned 0.26% of Zai Lab worth $7,427,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ZLAB. Pictet Asset Management Holding SA bought a new position in shares of Zai Lab in the fourth quarter valued at approximately $31,000. Barclays PLC lifted its position in Zai Lab by 337.6% in the fourth quarter. Barclays PLC now owns 3,702 shares of the company's stock worth $97,000 after purchasing an additional 2,856 shares during the period. US Bancorp DE increased its position in shares of Zai Lab by 1,671.9% during the 4th quarter. US Bancorp DE now owns 5,865 shares of the company's stock valued at $154,000 after purchasing an additional 5,534 shares during the period. Jasper Ridge Partners L.P. bought a new stake in shares of Zai Lab in the 4th quarter worth $210,000. Finally, Townsquare Capital LLC acquired a new stake in shares of Zai Lab in the fourth quarter valued at $243,000. Institutional investors and hedge funds own 41.65% of the company's stock.

Zai Lab Trading Down 3.6%

Shares of Zai Lab stock traded down $1.18 on Friday, reaching $31.32. 1,024,393 shares of the company were exchanged, compared to its average volume of 865,907. Zai Lab Limited has a fifty-two week low of $16.01 and a fifty-two week high of $39.77. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -11.31 and a beta of 1.04. The stock has a fifty day moving average price of $31.76 and a 200-day moving average price of $29.74.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.05. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The firm had revenue of $106.49 million for the quarter, compared to the consensus estimate of $118.40 million. On average, equities analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Ying Du sold 50,000 shares of the company's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the transaction, the chief executive officer now directly owns 494,117 shares of the company's stock, valued at approximately $17,032,212.99. The trade was a 9.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Yajing Chen sold 5,280 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.89, for a total value of $189,499.20. Following the sale, the chief financial officer now owns 25,471 shares of the company's stock, valued at $914,154.19. The trade was a 17.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 235,133 shares of company stock worth $7,416,861 over the last 90 days. 4.96% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on ZLAB shares. JPMorgan Chase & Co. lifted their target price on Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, March 13th. Bank of America reaffirmed a "neutral" rating and issued a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th. Finally, Scotiabank assumed coverage on shares of Zai Lab in a report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 target price for the company.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.